Independent NDC12 resource · Not affiliated with the FDA

Regulatory facts linked to current FDA sources  View FDA source

Check Readiness
FDA Dates and Milestones

NDC12 Timeline: Key FDA Dates Through 2036

The FDA published the final NDC12 rule on March 5, 2026. The rule takes effect on March 7, 2033, when FDA will begin assigning new 12-digit NDCs and convert existing FDA-assigned 10-digit NDCs to the uniform 12-digit format.

A three-year drug-labeling transition will then continue through March 6, 2036.

View The Complete Timeline
Plan Your Readiness
  • Confirmed FDA dates · Current final-rule timeline
  • Rule Effective
March 7, 2033

FDA begins assigning new NDC12 codes and converts previously assigned FDA NDCs to the 12-digit format.

Preparation

7 Years

Transition

3 Years

New format

12 Digits

Structure

6-4-2

Final rule published
March 5, 2026
Preparation period
2026–2033
Rule effective
March 7, 2033
Label transition ends
March 6, 2036
Confirmed FDA Timeline

The Most Important NDC12 Dates

These are the principal dates established by FDA’s final rule and supporting FDA information.
Date Milestone Status
November 5, 2018 FDA public hearing on the future NDC format Completed
July 25, 2022 Proposed NDC format rule published Completed
March 5, 2026 Final NDC12 rule published Completed
March 5, 2026–March 6, 2033 Seven-year preparation period In progress
March 7, 2033 Final rule takes effect Upcoming
March 7, 2033–March 6, 2036 Drug-labeling transition Upcoming
March 7, 2036 onward 10-digit NDC labeling may be subject to regulatory action Upcoming
FDA’s confirmed timeline replaces earlier estimates and uncertainty. Organizations should plan around the exact March 7, 2033 effective date and March 6, 2036 labeling milestone.
How the Timeline Developed

How Did the NDC12 Timeline Develop?

The move to a uniform NDC format developed through several years of public discussion, proposed rulemaking, industry feedback, and final FDA action.
November 5, 2018

FDA Holds a Public Hearing

FDA discussed the future format of the National Drug Code as the available supply of five-digit labeler codes became limited.

July 25, 2022

FDA Publishes the Proposed Rule

The proposed rule introduced the uniform 12-digit, 6-4-2 structure and requested feedback on format, timing, labeling, barcode requirements, and operational impact.

2022–2026

FDA Reviews Comments and Finalizes the Rule

FDA evaluated stakeholder comments and ultimately selected a seven-year delay between publication and the effective date.

March 5, 2026

FDA Publishes the Final NDC12 Rule

The final rule confirms the 12-digit 6-4-2 format, March 7, 2033 effective date, preparation period, labeling transition, conversion of prior NDC10 codes, and updated barcode provisions.

Current Phase

What Happens During the Seven-Year Preparation Period?

The preparation period began March 5, 2026 and continues through March 6, 2033.
During this period, FDA continues assigning NDCs in the current 10-digit configurations. Organizations should use the window to update systems, processes, infrastructure, and labeling for the 12-digit format.
Before March 7, 2033: Identify systems and workflows, confirm vendor roadmaps, update data structures and validation, review interfaces, prepare labeling and artwork, develop test scenarios, and coordinate cutover plans. These are planning activities rather than separate FDA deadlines.
Planning Guidance

Recommended Planning Checkpoints Before 2033

These checkpoints are NDC12.com planning recommendations, not additional FDA deadlines.
2026–2027

Organizations should establish program ownership and identify where NDCs are created, stored, displayed, converted, printed, scanned, or exchanged. Useful outputs may include:

  • System inventory
  • Data-flow map
  • Vendor inventory
  • Trading-partner inventory
  • Initial risk assessment
  • Governance structure
2027–2029

Teams can evaluate how the 12-digit format affects applications, databases, interfaces, labels, reports, and external dependencies.

This phase can also be used to:

  • Confirm vendor roadmaps
  • Identify unsupported applications
  • Define data and integration requirements
  • Prioritize high-risk dependencies
  • Estimate budgets and resources
2029–2031

Organizations can implement application, database, interface, reporting, labeling, and workflow changes.

The exact timing will depend on internal release cycles and vendor delivery schedules.

2031–2032

Testing should move beyond individual applications and include connected systems, external files, vendors, scanners, labels, reports, and trading partners.

2032–Mar 2033

The final period before the effective date should focus on:

  • End-to-end validation
  • Production deployment
  • Issue remediation
  • Operational training
  • Cutover procedures
  • Monitoring and support plans

Organizations should not treat these checkpoints as universally required dates. They provide a practical way to divide the confirmed seven-year preparation window into manageable phases.

Effective Date

What Changes on March 7, 2033?

Several NDC12 changes occur together on the effective date.

FDA Begins Assigning NDC12

New FDA-assigned NDCs use the uniform 6-4-2 structure.

Existing NDC10 Codes Are Converted

Previously assigned FDA NDCs are converted by adding leading zeros to the appropriate segments.

FDA Updates Drug-Listing Files

FDA plans to automatically update its drug-listing files to reflect the 12-digit format.

Systems Must Support the 12-Digit Format

Parties using FDA-assigned NDCs need systems capable of handling NDC12 on the effective date.

The Labeling Transition Begins

The three-year period for moving drug labeling from 10 digits to 12 digits begins.

Dual-Format Period

What Happens During the Three-Year Labeling Transition?

The labeling transition begins March 7, 2033 and continues through March 6, 2036.
During this period, products may display either the original 10-digit FDA-assigned NDC or the converted 12-digit FDA-assigned NDC. Systems should be capable of processing both formats.

The transition does not delay system readiness. March 7, 2033 remains the system-readiness date; the 2033–2036 period is specifically a labeling transition.

After the Transition

What Happens on March 7, 2036 and Beyond?

The FDA labeling transition runs through March 6, 2036.
FDA states that drugs labeled with a 10-digit NDC after March 7, 2036 may be subject to regulatory action. This does not mean every historical 10-digit value disappears from databases, archives, reports, or transaction history.
Operational View

NDC12 Timeline by Workstream

Different workstreams interact with the timeline in different ways.
Workstream Before March 7, 2033 March 7, 2033 Through March 6, 2036
FDA assignments Current 10-digit formats continue New assignments use NDC12 NDC12 remains the native FDA format
Existing NDCs Existing NDC10 values remain current FDA converts them to 12 digits Both representations may remain relevant during transition
Systems Prepare, remediate, and test Must support Should support both 10- and 12-digit formats
Drug labeling Prepare revised labeling NDC12
Label transition begins		 Complete updates and use remaining old stock
Drug-listing files Prepare for format change FDA automatically updates files Registrants update listings when labels are updated
Historical data Inventory and plan normalization Preserve crosswalks and traceability Continue managing old and new representations
Scope Clarity

What Deadlines Does the FDA Rule Not Establish?

The final rule does not assign separate regulatory deadlines to every internal implementation task.
Examples include system inventory completion, vendor contracts, application development, partner testing, user training, data conversion, legacy-system retirement, and the separate HIPAA transaction-standard update. Organizations must create their own internal milestones early enough to achieve readiness by March 7, 2033.
Quick Answers

Frequently Asked Questions About the NDC12 Timeline

Concise answers to the most common timing and transition questions.
FDA published the final rule on March 5, 2026. The rule does not take effect until March 7, 2033. The period between those dates is the seven-year preparation period.
No. March 7, 2033 is the effective date for the new FDA-assigned format. A three-year labeling transition permits continued use of existing 10-digit NDCs on drug labels through March 6, 2036.
Yes. FDA advises affected parties to ensure their systems can handle both the 10-digit and 12-digit formats during the March 7, 2033–March 6, 2036 transition.
FDA will convert previously assigned 10-digit NDCs to the uniform 12-digit format by adding leading zeros to the appropriate segments.
FDA plans to update drug-listing files automatically to reflect the 12-digit format. Registrants will not need to submit new files solely because of the conversion.
The transition runs through March 6, 2036. FDA states that drugs labeled with a 10-digit NDC after March 7, 2036 may be subject to regulatory action.
Not through this final rule. The FDA rule applies to FDA-assigned NDCs and does not itself amend the separate HIPAA transaction standards.
View All NDC12 FAQs
Prepare for NDC12

Start Your NDC12 Readiness Assessment

Identify how NDC12 may affect your systems, data, labeling, workflows, vendors, and trading partners.
Start the NDC12 Readiness Assessment
Stay Updated

Stay Informed as NDC12 Develops

Receive important NDC12 updates, regulatory developments, implementation guidance, and new resources directly by email.